SubjectWell Raises $10M to Expand Its Risk-Free Patient Recruitment Marketplace

SubjectWell , the risk-free clinical trials marketplace for patient recruitment, announced today its $10 million in Series A funding led by Windham Venture Partners , with participation from previous investors Healthy Ventures and Geekdom Fund .

Information
Content
Key Points: 
  • SubjectWell , the risk-free clinical trials marketplace for patient recruitment, announced today its $10 million in Series A funding led by Windham Venture Partners , with participation from previous investors Healthy Ventures and Geekdom Fund .
  • By building awareness and creating the first true trial marketplace, we provide patients with greater choice and access to innovative treatments.
  • Our growth is not just deepening the patient pool, said Tony Averbeck , vice president of business development at SubjectWell.
  • SubjectWell, the risk-free clinical trials marketplace for patient recruitment, is raising awareness of clinical research in the general population and providing patients more choice and easy access to innovative treatment options.


SubjectWell,
the risk-free clinical trials marketplace for patient recruitment,
announced today its $10 million in Series A funding led by Windham
Venture Partners
, with participation from previous investors Healthy
Ventures
and Geekdom
Fund
. This funding bolsters SubjectWell’s mission of building
awareness of and increasing participation in clinical research by
providing a single marketplace that allows prospective patients to match
to any available clinical trials.

“The largest barrier to participation in clinical trials is awareness —
patients aren’t aware clinical trials exist and don’t know how to get
started,” said Ivor
Clarke
, CEO at SubjectWell. “By building awareness and creating the
first true trial marketplace, we provide patients with greater choice
and access to innovative treatments. Our investors’ support allows us to
reach more interested patients and fill our clients’ studies faster.”

This round of funding will support SubjectWell’s international expansion
by helping the company extend its services beyond North America and into
Europe, South America, and the United Kingdom.

“Our growth is not just deepening the patient pool,” said Tony
Averbeck
, vice president of business development at SubjectWell.
“Our performance-based pricing model, where we’re only compensated for
patients who randomize, is specifically designed to allow every sponsor
to bring all of their trials into SubjectWell’s marketplace.”

“Despite all the recent advances in medicine, clinical trials continue
to be a major pain point for stakeholders. The vast majority of trials
are delayed and many ultimately fail due to poor patient selection,”
said Adam
Fine
, general partner and CEO at Windham. “We have looked deeply at
the clinical trial space and concluded that SubjectWell, with hundreds
of studies already recruiting through its marketplace, has demonstrated
the most effective model for enrolling clinical trials. We are excited
to partner with this terrific team.”

About SubjectWell
SubjectWell, the risk-free clinical trials
marketplace for patient recruitment, is raising awareness of clinical
research in the general population and providing patients more choice
and easy access to innovative treatment options. Visit www.subjectwell.com
to find out more.

About Windham
Windham Venture Partners is a NY-based venture
capital firm focused on healthcare, with particular interest in medtech
and healthcare IT.

Windham partners with exceptional entrepreneurs and companies that are
developing game-changing technologies to serve unmet needs, improve
outcomes and help the lives of large numbers of patients. Windham is led
by seasoned healthcare industry executives, operators and investors.